# Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)

> **NCT06371482** · PHASE2 · RECRUITING · sponsor: **Hebei Medical University Fourth Hospital** · enrollment: 58 (estimated)

## Conditions studied

- SCLC, Limited Stage

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Chemotherapy drug of EP regimen
- **RADIATION:** radiotherapy

## Key facts

- **NCT ID:** NCT06371482
- **Lead sponsor:** Hebei Medical University Fourth Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2024-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06371482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06371482, "Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06371482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*